Ruxolitinib (NCT02974647)

Name: Ruxolitinib trial for Lymphoma (NCT02974647)
Uploaded: 2026-10-31T23:03:56.774Z
Duration: 1 min 10 s
Description: Ruxolitinib trial for Lymphoma (NCT02974647). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02974647.

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma: a one-minute explainerNCT029746471 min

Ruxolitinib trial for Lymphoma (NCT02974647). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with T-cell or NK-cell lymphoma, usually after failure of systemic treatment. Certain leukemia and lymphoproliferative subtypes, and other patients approved by the lead investigator, may enter untreated.

The idea: ruxolitinib blocks JAK signaling involved in cancer-cell survival. Patients take 20 milligrams by mouth twice daily in 28-day cycles. Groups differ by JAK/STAT findings; a mutation is not required for every group. Researchers assess disease control and safety.

This phase 2 study plans 83 patients. Alison Moskowitz leads at Memorial Sloan Kettering, with six recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.